ATRT Research Update
- hope4atrt
- Jun 1
- 1 min read
Lantern Pharma Inc. (Nasdaq: LTRN)'s drug candidate, LP-184 shows promising in-vivo activity in Atypical Teratoid Rhabdoid Tumors at 2025 Society for Neuro-Oncology Pediatric Conference.
Independent research from Johns Hopkins Medicine, presented by Dr. Eric Raabe at the 2025 SNO Pediatric Neuro-Oncology Conference, supports Lantern’s data that led to their FDA Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 for the treatment of ATRT.
In-Vivo Data Highlights:
In-vivo mice models, CHLA06 and BT37, showed survival of increases of 345% and 44% respectively.
Potent anti-tumor activity across multiple ATRT subtypes (MYC, TYR, SHH)
Strong blood-brain barrier penetration (Cmax: 730 nM)
Increased apoptosis(programmed cell death), reduced proliferation in ATRT cancer cells
Significant survival benefit in two orthotopic xenograft models
No observed toxicity in vivo
These findings support the planned pediatric clinical trial of LP-184 expected to begin in late 2025 or early 2026.
View the full press release: https://bit.ly/4jrJqF8
留言